While drug development is a long and arduous process, it is far more difficult to produce a vaccine. That's what Sanofi Pasteur Exec VP David Loew learned after moving from the pharma side of the business to vaccines.
"We see that there are less new molecular entities" for vaccines than in oncology, Loew said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?